Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor

Eur J Med Chem. 2011 Apr;46(4):1207-21. doi: 10.1016/j.ejmech.2011.01.040. Epub 2011 Feb 3.

Abstract

Bivalent ligands constituted by two identical pharmacophores structurally related to the Nociceptin Opioid Receptor (NOPr) antagonist JTC-801 were synthesized and their binding affinities for NOPr were evaluated. The novel ligands are formed by two modified JTC-801 units linked by di-iminic and di-aminic spacers with length ranging from three to ten methylene units. Moreover, the synthesis and the pharmacological characterization were extended to the corresponding univalent ligands. The latter compounds consisted in a single modified JTC-801 unit and an alkyl or alkylamino or alkylimino tail. The purpose of this study is to feature the location and surroundings of the allosteric binding site(s) of pharmacophores containing the 4-aminoquinoline structure. Most important, the bivalent ligands were exploited to reveal the eventual occurrence of a supramolecular receptorial architecture of the NOPr. All the bivalent derivatives 4 and 5 proved to be active in the nanomolar range with no outstanding dependence on the chain length. They showed potencies from three to ten times higher than the corresponding monomers. Consequently, results clearly indicated a positive role of the second pharmacophore in the ligand-protein interaction. The pharmacological profile of the monomers 7 and 8 clarified the contribution of the linker chain to NOP receptor affinity and suggested the presence of a lipophilic acidic site neighbouring the binding site of the JTC-like ligands. Selectivity of saturated compounds 5, 7, and 8 was tested by binding experiments on δ, κ and μ opioid receptors. Results indicated a general loss of selectivity as compared to JTC-801. In the [(35)S]GTPγS binding assay, all the compounds revealed antagonistic properties at the NOP Receptor. In conclusion the present study set the basis for a systematic investigation on the structural modifications that can be introduced into novel ligands for NOPr and helped to feature the surrounds of the allosteric site of NOPr.

MeSH terms

  • Aminoquinolines / chemical synthesis
  • Aminoquinolines / chemistry*
  • Aminoquinolines / pharmacology*
  • Benzamides / chemical synthesis
  • Benzamides / chemistry*
  • Benzamides / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Narcotic Antagonists* / chemical synthesis
  • Narcotic Antagonists* / chemistry*
  • Narcotic Antagonists* / pharmacology*
  • Nociceptin Receptor
  • Receptors, Opioid

Substances

  • Aminoquinolines
  • Benzamides
  • N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide
  • Narcotic Antagonists
  • Receptors, Opioid
  • Nociceptin Receptor
  • OPRL1 protein, human